Kura Oncology Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
192
- Stock Symbol
-
KURA
- Investments
-
1
- Share Price
-
$6.02
- (As of Friday Closing)
Kura Oncology General Information
Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Contact Information
Website
www.kuraoncology.comCorporate Office
- 12730 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
Corporate Office
- 12730 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
Kura Oncology Stock Performance
As of 16-May-2025, Kura Oncology’s stock price is $6.02. Its current market cap is $521M with 86.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.02 | $5.95 | $5.41 - $23.48 | $521M | 86.6M | 1.26M | -$2.10 |
Kura Oncology Financials Summary
As of 31-Mar-2025, Kura Oncology has a trailing 12-month revenue of $68M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (177,818) | 238,654 | 632,864 | 424,764 |
| Revenue | 67,991 | 53,883 | 0 | 0 |
| EBITDA | (202,588) | (192,347) | (164,955) | (139,106) |
| Net Income | (181,887) | (173,983) | (152,631) | (135,840) |
| Total Assets | 743,764 | 760,159 | 448,935 | 456,306 |
| Total Debt | 19,354 | 16,594 | 17,200 | 14,024 |
Kura Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kura Oncology Comparisons
Industry
Financing
Details
Kura Oncology Competitors (70)
One of Kura Oncology’s 70 competitors is Syndax, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Syndax | Formerly VC-backed | Waltham, MA | ||||
| SpringWorks Therapeutics | Formerly VC-backed | Stamford, CT | ||||
| Oncorus | Formerly VC-backed | Andover, MA | ||||
| Sagimet Biosciences | Formerly VC-backed | San Mateo, CA | ||||
| Ikena Oncology | Formerly VC-backed | Boston, MA |
Kura Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kura Oncology Patents
Kura Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250101035-A1 | Crystalline forms of a menin inhibitor | Pending | 17-Jul-2023 | ||
| US-20250099469-A1 | Pharmaceutical compositions comprising a menin inhibitor | Pending | 17-Jul-2023 | ||
| AU-2024220205-A1 | Solid forms of a macrocyclic farnesyltransferase inhibitor and formulations thereof, and methods of preparing and using the macrocyclic compound and its solid forms | Pending | 31-May-2023 | ||
| US-20240024301-A1 | Methods of treating head and neck squamous cell carcinoma | Pending | 08-Apr-2022 | ||
| EP-4504192-A1 | Methods of treating head and neck squamous cell carcinoma | Pending | 08-Apr-2022 | A61K31/4439 |
Kura Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kura Oncology Acquisitions (1)
Kura Oncology’s most recent deal was a Merger/Acquisition with Zeta Acquisition. The deal was made on 06-Mar-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zeta Acquisition | 06-Mar-2015 | Merger/Acquisition | Holding Companies |
Kura Oncology ESG
Risk Overview
Risk Rating
Updated March, 01, 2024
24.56 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Biotechnology
Subindustry
of 365
Rank
Percentile
Kura Oncology FAQs
-
When was Kura Oncology founded?
Kura Oncology was founded in 2014.
-
Where is Kura Oncology headquartered?
Kura Oncology is headquartered in San Diego, CA.
-
What is the size of Kura Oncology?
Kura Oncology has 192 total employees.
-
What industry is Kura Oncology in?
Kura Oncology’s primary industry is Biotechnology.
-
Is Kura Oncology a private or public company?
Kura Oncology is a Public company.
-
What is Kura Oncology’s stock symbol?
The ticker symbol for Kura Oncology is KURA.
-
What is the current stock price of Kura Oncology?
As of 16-May-2025 the stock price of Kura Oncology is $6.02.
-
What is the current market cap of Kura Oncology?
The current market capitalization of Kura Oncology is $521M.
-
What is Kura Oncology’s current revenue?
The trailing twelve month revenue for Kura Oncology is $68M.
-
Who are Kura Oncology’s competitors?
Syndax, SpringWorks Therapeutics, Oncorus, Sagimet Biosciences, and Ikena Oncology are some of the 70 competitors of Kura Oncology.
-
What is Kura Oncology’s annual earnings per share (EPS)?
Kura Oncology’s EPS for 12 months was -$2.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
